

7. Centrifuge tubes at 10,000 rpm for 5 min in the Heraeus Microfuge to separate the organic and aqueous layers. Transfer 0.70 ml of the organic (upper) phase to a 10 x 75 mm disposable glass tubes, and evaporate sample to dryness at room temp using the N2-EVAP nitrogen evaporator.

8. Add 60 µl of Reagent F to each tube, cover with a plastic cap, vortex briefly, and sonicate for 5 min in a bath-type sonicator to **completely** resolubilize residues. Process samples by HPLC as described below or store @ -20°C until HPLC analysis can be performed.

NOTE A - Blanks for this assay contain all components except NADPH (Reagent C). Standard curves are constructed by adding 2.5, 5, 10, and 15 µl of Reagent G (equivalent to 2.5, 5, 10, and 15 nmol nifedipine pyridine metabolite) to the assay tubes with NADPH OMITTED, and performing the assay as described above.

III. HPLC ANALYSIS CONDITIONS FOR NIFEDIPINE

Column: Waters Sunfire (3.0 x 150 mm) w/ Security Guard STD Guard Column

Mobile Phase: **Solvent A** – 0.05% Phosphoric Acid

Solvent B – 100% MeOH

Flow Rate: 0.75 ml/min

Column Temp: Ambient

Sample Temp: Ambient

Peak Detection: 254 nm


Run Time: 16 min

Injection Volume: 30 µl

(min)	(%A)	(%B)	(ml/min)	
Initial	50	50	0.75	--
10	20	80	0.75	6
10.1	50	50	0.75	1

Using these HPLC conditions, NPM (nifedipine pyridine metabolite) elutes at **4.9 MIN** while the parent compound nifedipine elutes at **6.8 min** (see attached chromatogram).




REFERENCE: Guengerich FP *et al* : Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. *J. Biol. Chem.* 26:5051-5060, 1986.



NIFEDIPINE CONVERSION TO NIFEDIPINE PYRIDINE METABOLITE BY CYP3A4/CYP3A5

Nifedipine = 3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate.

NIFEDIPINE – CYP3A4



HPLC analysis of nifedipine oxidation by human liver microsomes. Nifedipine (NIF; 200 μ M) was incubated with human liver microsomes (0.24 mg protein, 0.1 nmol aggregate P450) for 20 min at 37°C in the presence of NADPH plus 0.5 mg anti-CYP1A2, anti-CYP3A4 IgG or control (preimmune) IgG. NIF was then resolved from the nifedipine pyridine metabolite (NPM) metabolite formed by reversed-phase HPLC as described above using a Waters Alliance unit equipped with a model 2690 separation module and a model 2487 UV/VIS detector. A Waters Sunfire C18 column (3.0 mm x 15 cm, 5 μ m particle size) was utilized. Gradient elution was performed with a mobile phase consisting of methanol:0.05% phosphoric acid (see above) employing a flow rate of 0.75 ml/min, and the column eluates were continuously monitored for UV absorbance at 254 nm. Under these conditions, NPM and NIF exhibited retention times of 4.9 and 6.7 min, respectively; the total sample analysis time was 16 min. Formation of NPM was determined by comparison of peak areas with those of analytical metabolite standards.

- a) NIF + liver microsomes + NADPH + Preimmune IgG
- b) NIF + liver microsomes + NADPH + Anti-CYP1A2 IgG
- c) NIF + liver microsomes + NADPH + Anti-CYP3A4 IgG